Healthcare Utilization in Children Following Hospitalization for RSV‐ Versus Non‐RSV Related Lower Respiratory Tract Infections: A Nationwide Retrospective Study
Pediatric Pulmonology · 2026
DOI: 10.1002/ppul.71455 ↗At a glance
Journal article in Pediatric Pulmonology, 2026. Written by Guy Hazan and 4 co-authors. Institution: Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel. Major MEDLINE topics: Respiratory Syncytial Virus Infections, Hospitalization, Respiratory Tract Infections, Patient Acceptance of Health Care. Cited 3 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Sanofi, AstraZeneca.
Topics: Kinderkrankenpflege
Abstract (original language)
Introduction
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in young children. Additionally, RSV is associated with long‐term respiratory morbidities. This study evaluates acute and long‐term healthcare utilization (HCU) in infants hospitalized with RSV‐associated LRTI (RSV‐LRTI) compared to non‐RSV LRTI (Non‐RSV‐LRTI) in a nationwide cohort.
Methods
A retrospective case‐control study used data from Clalit Healthcare Services (CHS), Israel's largest healthcare provider. Infants born between 2015 and 2023, admitted before 12 months of age with LRTI during the RSV season, were included. PCR confirmed RSV‐LRTI cases, while controls had negative RSV PCR and positive PCR for other respiratory viruses. Acute HCU was assessed within 30 days post‐discharge. Long‐term respiratory‐related HCU was evaluated up to 6 years of age. Statistical analyses included Poisson regression, adjusting for demographic and clinical potential confounders.
Results
A total of 8626 infants were included, with 4,951 in the RSV‐LRTI group and 3675 in the Non‐RSV‐LRTI group. The adjusted acute HCUs were higher in RSV‐LRTI cases with increased systemic steroid use (IRR = 2.25, 95%CI: 1.94–2.62, p < 0.001) and short‐acting beta‐agonist use (IRR = 3.80, 95%CI: 3.36–4.30, p < 0.001). The adjusted long‐term HCU trends persisted, with significantly higher use of respiratory‐related medications and pediatric pulmonologist visits (IRR = 1.21, 95%CI: 1.06–1.40, p = 0.006) in the RSV‐LRTI group.
Conclusion
This nationwide study highlights the substantial acute and long‐term HCU burden associated with RSV‐LRTI compared to Non‐RSV‐LRTI, underscoring the need for effective preventive strategies for all infants, especially in the first months of life.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel.
- Pediatric Pulmonary Unit, Saban's Children Hospital, Soroka University Medical Center, Beer-Sheva, Israel.
- Research and Innovation Center, Soroka University Medical Center, Beer-Sheva, Israel.
- Sanofi Israel Ltd, Vaccines Medical, Yakum, Israel.
- Sanofi A/S, Vaccines Medical, Copenhagen, Denmark.
- Pediatric Infectious Diseases Unit, Saban's Children Hospital, Soroka University Medical Center, Beer-Sheva, Israel.
ORCID profiles: Guy Hazan, Oliver Martyn
Funding
- Sanofi
- AstraZeneca
Cite
APA
Hazan, G., Ofri, M., Hertz, L., Martyn, O., & Greenberg, D. (2026). Healthcare Utilization in Children Following Hospitalization for RSV‐ Versus Non‐RSV Related Lower Respiratory Tract Infections: A Nationwide Retrospective Study. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71455
Vancouver
Hazan G, Ofri M, Hertz L, Martyn O, Greenberg D. Healthcare Utilization in Children Following Hospitalization for RSV‐ Versus Non‐RSV Related Lower Respiratory Tract Infections: A Nationwide Retrospective Study. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71455
BibTeX
@article{Hazan2026,
author = {Hazan, Guy and Ofri, Mai and Hertz, Lital and Martyn, Oliver and Greenberg, David},
title = {Healthcare Utilization in Children Following Hospitalization for RSV‐ Versus Non‐RSV Related Lower Respiratory Tract Infections: A Nationwide Retrospective Study},
journal = {Pediatric Pulmonology},
year = {2026},
doi = {10.1002/ppul.71455}
}
EUVIMED